Physician profile
Kevin J Winders
NPI 1275577520
$225,383.93
in general payments reported to CMS, 2019-2025
30 companies · $12K in 2025
The $12K reported for 2025 was more than what 98% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $23K · 2021: $57K · 2022: $37K · 2023: $29K · 2024: $12K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50K · Travel and Lodging: $1,860 · Food and Beverage: $1,805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50,100.00 |
| Travel and Lodging | $1,859.86 |
| Food and Beverage | $1,805.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $115,584.69 | 2021-2025 | Vraylar |
| Allergan, INC. | $69,858.60 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $24,857.75 | 2021-2024 | Qelbree, Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $9,877.82 | 2019-2022 | |
| Corium, LLC | $557.25 | 2021-2023 | Azstarys |
| Teva Pharmaceuticals USA, INC. | $467.58 | 2022-2025 | Uzedy, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $449.27 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $436.38 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $385.68 | 2019-2022 | |
| Adlon Therapeutics L.P. | $348.80 | 2019-2021 | |
| Neos Therapeutics, Lp | $315.05 | 2019-2022 | |
| Bausch Health US, LLC | $314.17 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $310.23 | 2020-2022 | |
| Tris Pharma INC | $304.42 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $246.36 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $206.89 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $161.12 | 2019-2022 | |
| Eisai INC. | $101.90 | 2020-2021 | |
| Shire North American Group INC | $100.95 | 2019 | |
| Alkermes, INC. | $93.67 | 2021-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $84.45 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $76.55 | 2019-2025 | Fanapt |
| Neurocrine Biosciences, INC. | $61.62 | 2021-2025 | |
| Arbor Pharmaceuticals, INC. | $59.25 | 2019-2020 | |
| Harmony Biosciences LLC | $42.51 | 2021 | |
| Idorsia Pharmaceuticals US INC | $19.15 | 2022 | |
| Amag Pharmaceuticals, INC. | $18.38 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.27 | 2022 | |
| Alfasigma USA, INC. | $13.46 | 2020 | |
| Neuronetics, INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Winders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.